Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length
Open Access
- 15 March 2024
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 112 (9) , 1494-1505
Abstract
RNA‐based therapeutics have gained traction for the prevention and treatment of a variety of diseases. However, their fragility and immunogenicity necessitate a drug carrier. Lipid nanoparticles (LNPs) have emerged as the predominant delivery vehicle for RNA therapeutics. An important component of LNPs is the ionizable lipid (IL), which is protonated in the acidic environment of the endosome, prompting cargo release into the cytosol. Currently, there is growing evidence that the structure of IL lipid tails significantly impacts the efficacy of LNP‐mediated mRNA translation. Here, we optimized IL tail length for LNP‐mediated delivery of three different mRNA cargos. Using C12‐200, a gold standard IL, as a model, we designed a library of ILs with varying tail lengths and evaluated their potency in vivo. We demonstrated that small changes in lipophilicity can drastically increase or decrease mRNA translation. We identified that LNPs formulated with firefly luciferase mRNA (1929 base pairs) and C10‐200, an IL with shorter tail lengths than C12‐200, enhance liver transfection by over 10‐fold. Furthermore, different IL tail lengths were found to be ideal for transfection of LNPs encapsulating mRNA cargos of varying sizes. LNPs formulated with erythropoietin (EPO), responsible for stimulating red blood cell production, mRNA (858 base pairs), and the C13‐200 IL led to EPO translation at levels similar to the C12‐200 LNP. The LNPs formulated with Cas9 mRNA (4521 base pairs) and the C9‐200 IL induced over three times the quantity of indels compared with the C12‐200 LNP. Our findings suggest that shorter IL tails may lead to higher transfection of LNPs encapsulating larger mRNAs, and that longer IL tails may be more efficacious for delivering smaller mRNA cargos. We envision that the results of this project can be utilized as future design criteria for the next generation of LNP delivery systems for RNA therapeutics.Keywords
Funding Information
- National Institutes of Health (DP2 TR002776)
- Canadian Aeronautics and Space Institute
- American Cancer Society (RSG‐22‐122‐01‐ET)
- National Institute of Dental and Craniofacial Research (T90DE030854)
- National Science Foundation (1845298)
- Vagelos Institute for Energy Science and Technology, University of Pennsylvania
This publication has 72 references indexed in Scilit:
- Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the PlacentaSmall, 2023
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseasesActa Biomaterialia, 2021
- A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to LeukocytesAdvanced Materials, 2020
- Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type IAdvanced Materials, 2018
- Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNAAngewandte Chemie, 2016
- The SAMPL5 challenge for embedded-cluster integral equation theory: solvation free energies, aqueous pK a, and cyclohexane–water log DJournal of Computer-Aided Molecular Design, 2016
- Zeta Potential Measurement2010
- Atomic Physicochemical Parameters for Three‐Dimensional Structure‐Directed Quantitative Structure‐Activity Relationships I. Partition Coefficients as a Measure of HydrophobicityJournal of Computational Chemistry, 1986
- The size distributions of proteins, mRNA, and nuclear RNAJournal of Molecular Evolution, 1980